Overview
VDRL stands for Venereal Disease Research Laboratory test. It is a commonly used serological test for the diagnosis of syphilis. The test is based on the principle of slide flocculation and is classified as a non-treponemal test. It does not detect the causative organism directly but identifies antibodies produced in response to infection.
The test detects reagin antibodies present in the patient’s serum. These antibodies react with a cardiolipin antigen preparation to produce visible flocculation. Due to its simplicity and rapid performance, the test is widely used as a screening method for syphilis.
Principle
The principle of the VDRL test is based on the formation of antigen-antibody complexes. When a person is infected, the body produces antibodies that react with cardiolipin antigen. The antigen used in this test is a colorless alcoholic solution containing cardiolipin, cholesterol, and lecithin.
Cardiolipin antigen reacts non-specifically with reagin antibodies of the IgM and IgG classes present in the serum. This reaction leads to the formation of floccules, which can be visualized microscopically. Since the test detects antibodies and not the organism itself, it is categorized as a non-specific test.
Procedure
Patient serum is first collected and heated at 56°C for 30 minutes. This step inactivates complement proteins that may interfere with the reaction. After heating, the serum is allowed to cool to room temperature before testing.
A measured volume of diluted cardiolipin antigen suspension is added to a measured amount of patient serum on a glass slide containing wells. The antigen may be prepared from tissue cardiolipin or chemically synthesized cardiolipin.
The slide is then rotated gently for about four minutes to allow proper mixing of antigen and antibody. After rotation, the slide is examined under a microscope using a low-power objective to detect the presence or absence of flocculation.
Interpretation
A reactive result is reported when large or medium-sized antigen-antibody clumps are observed. This indicates a positive reaction suggestive of syphilis infection. A weakly reactive result is seen when only small-sized clumps are present.
A non-reactive result is reported when no clumping is observed. In such cases, no detectable reagin antibodies are present in the serum. All reactive and weakly reactive samples require further testing by serial dilution to determine the antibody titer.
Estimation of antibody titer helps in assessing disease activity and monitoring response to treatment.
Uses
The VDRL test is one of the most widely used screening tests for syphilis. It is simple, rapid, and cost-effective, making it suitable for large-scale screening programs.
It is also used in the investigation of other treponemal infections such as yaws and pinta. The test shows high sensitivity in secondary syphilis and moderate sensitivity in primary and late stages of the disease.
Due to its high specificity, the test is useful in identifying potential infections when used in combination with clinical findings.
Advantages
One of the major advantages of the VDRL test is its usefulness in monitoring response to treatment. A decreasing antibody titer indicates effective therapy and clinical improvement.
The test can also be performed on cerebrospinal fluid for the detection of antibodies in cases of neurosyphilis. Reagin antibodies usually become detectable within 7 to 10 days after the appearance of the primary chancre.
Because of its simplicity, the test can be repeated easily during follow-up.
Limitations
The VDRL test is a non-specific test and may produce false results. One important limitation is the prozone phenomenon, where excess antibodies prevent visible flocculation and lead to false-negative results.
This issue can be corrected by performing serial dilutions of the serum. Sensitivity of the test decreases in the late stages of syphilis.
Biological false-positive reactions may occur in a small percentage of cases. These reactions are seen in conditions such as leprosy, malaria, viral hepatitis, HIV infection, pregnancy, and intravenous drug abuse.
